Attachment: form8-k.htm


 

eXHIBIT 3.2

 

Amendment to the Amended and Restated By-laws

of CytRx Corporation

 

Pursuant to Article Ninth of the Restated Certificate of Incorporation of CytRx Corporation, a Delaware corporation (the “Company”), Article VIII of the Amended and Restated By-laws of the Company (as amended heretofore, the “By-laws”) of the Corporation, and Section 109 of the General Corporation Law of the State of Delaware, on the date hereof, the By-laws of the Company are hereby amended as follows:

 

The paragraph titled “QUORUM” in Section 3 of Article II is hereby deleted in its entirety and replaced with the following By-law:

 

“QUORUM. The holders of one-third of the outstanding shares of stock entitled to vote thereat shall constitute a quorum at a meeting of stockholders for the transaction of any business, but if at any meeting there shall be less than a quorum present, the chairman of the meeting may, to the extent permitted by law, adjourn the meeting from time to time until a quorum shall be present or represented.”

 

IN WITNESS WHEREOF, this amendment to the By-laws of the Company is executed on May 19, 2022.

 

  By: /s/ John Y. Caloz
  Name: John Y. Caloz
  Title: Chief Financial Officer

 

 

 

 

 


 

EXHIBIT 3.3

 

STATE OF DELAWARE
CERTIFICATE OF CORRECTION

 

CytRx Corporation, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows:

 

1.The name of the corporation is CytRx Corporation.
   
2.That a Certificate of Amendment to Restated Certificate of Incorporation of CytRx Corporation (the “Certificate”) was filed with the Secretary of State of Delaware on March 16, 2022 and that said Certificate requires correction as permitted by Section 103 of the General Corporation Law of the State of Delaware.
   
3.The inaccuracy or defect of said Certificate is: The first paragraph of Article FOURTH incorrectly states that the par value per share of CytRx Corporation preferred stock is $0.1 per share, when it should state that such par value is $0.01 per share.
   
4.The Article FOURTH of the Certificate is corrected to read as follows:

 

FOURTH. The total number of shares of all classes of stock that the corporation shall have the authority to issue is Sixty-Three Million Two Hundred Twenty-Seven Thousand Two-Hundred Seventy-Three (63,227,273), of which Sixty-Two Million Three Hundred Ninety-Three Thousand Nine Hundred Forty (62,393,940) shall be common stock, par value $0.001 per share (the “Common Stock”), and Eight Hundred Thirty-Three Thousand Three Hundred Thirty-Three (833,333) shall be preferred stock, par value $0.01 per share (the “Preferred Stock”).

 

The Board of Directors is hereby authorized, subject to any limitations prescribed by law, to provide for the issuance of the shares of Preferred Stock in series, and by filing a Certificate pursuant to the applicable law of the State of Delaware (hereinafter referred to as a “Preferred Stock Designation”), to establish from time to time the number of shares to be included in each such series, and to fix the designations, powers, preferences, and rights of the shares of each such series, any qualifications, limitations or restrictions thereof.”

 

IN WITNESS WHEREOF, said corporation has caused this Certificate of Correction this 19th day of May, 2022.

 

  By: /s/ John Y. Caloz
  Name: John Y. Caloz
  Title: Chief Financial Officer

 

 

 

 


 

Exhibit 99.1

 

CytRx Announces Distribution of Series D Preferred Stock to
Holders of its Common Stock

 

LOS ANGELES May 19, 2022, CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 pm Eastern Time on May 20, 2022. The outstanding shares of Series D Preferred Stock will vote together with the outstanding shares of the Company’s common stock, as a single class, exclusively with respect to a proposal to give the Company’s Board of Directors discretion to implement a reverse stock split in connection with satisfying the initial listing requirements of a national securities exchange, as well as any proposal to adjourn any meeting of stockholders called for the purpose of voting on the reverse stock split, and will not be entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law. Subject to certain limitations, each outstanding share of Series D Preferred Stock will have 1,000,000 votes per share (or 1,000 votes per one one-thousandth of a share of Series D Preferred Stock).

 

All shares of Series D Preferred Stock that are not present in person or by proxy at the meeting of stockholders held to vote on the reverse stock split as of immediately prior to the opening of the polls at such meeting will automatically be redeemed by the Company. Any outstanding shares of Series D Preferred Stock that have not been so redeemed will be redeemed if such redemption is ordered by the Company’s Board of Directors or automatically upon the approval by the Company’s stockholders of an amendment to the Company’s certificate of incorporation effecting the reverse stock split at such meeting.

 

The Series D Preferred Stock will be uncertificated, and no shares of Series D Preferred Stock will be transferable by any holder thereof except in connection with a transfer by such holder of any shares of the Company’s common stock held by such holder. In that case, a number of one one-thousandths of a share of Series D Preferred Stock equal to the number of shares of the Company’s common stock to be transferred by such holder would be transferred to the transferee of such shares of common stock.

 

Further details regarding the Series D Preferred Stock will be contained in a report on Form 8-K to be filed by the Company with the Securities and Exchange Commission.

 

 
 

 

Forward-Looking Statements

 

This press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead represent only CytRx’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of CytRx’s control. Forward-looking statements often include words such as “anticipates,” “estimates,” “expects,” “projects,” “forecasts”, “intends,” “plans,” “believes”, “suggest”, “estimate”, “target”, “should”, “could”, “would”, “may”, “might”, or “will” and words and terms of similar import. Forward-looking statements involve known and unknown risks, uncertainties and other factors, many of which are outside our control. Forward-looking statements include, but are not limited to, statements about our market opportunity and the potential growth of that market, potential receipt of EMA and FDA approvals, potential receipt of future milestone and royalty payments, our strategies (including with regard to stock splits), and trends in our industry and markets, all of which may be affected by, among others, adverse changes in general economic and market conditions. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements; and other risks and uncertainties described in the most recent annual and quarterly reports filed by the CytRx with the SEC, including disclosures under the heading “Risk Factors”, and current reports filed since the date of the CytRx’s most recent annual report. All forward-looking statements are based upon information available to the CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

About CytRx

 

CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer. CytRx’s most recent advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, CytRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S in exchange for milestone payments and royalties. Orphazyme is developing arimoclomol in two indications, including Niemann-Pick disease Type C (NPC), and Gaucher disease. CytRx Corporation’s website is www.cytrx.com.

 

Contacts

 

Longacre Square Partners

Greg Marose / Bela Kirpalani

cytrx@longacresquare.com

 

 

 

 

 


cytr-20220519.xsd
Attachment: cytr-20220519.xsd


cytr-20220519_lab.xml
Attachment: cytr-20220519_lab.xml


cytr-20220519_pre.xml
Attachment: cytr-20220519_pre.xml